News

Presented certificates of IDIBELL summer internships

On December 2nd was held the awarding of diplomas to the ten students who have completed the summer internship at IDIBELL. The event was chaired by the Director General of IDIBELL, Emilià Pola. Also attending the scientific director, Gabriel Capellà, the scientific deputy director, Marga Nadal and the researchers Isabel Fabregat, Cristina Muñoz-Pinedo, Merce Perez, […]

Leer más about Presented certificates of IDIBELL summer internships

Jordi Sunyer: “Our prenatal environment is fundamental in our mental development”

Air pollution is one of the most common environmental hazards that affect up to 100% of the population from birth to death. The co-director of CREAL (Centre for Research in Environmental Epidemiology), Jordi Sunyer, explained in the seminar series IDIBELL his research in this field. Several studies have shown that environmental exposures and nutrition during […]

Leer más about Jordi Sunyer: “Our prenatal environment is fundamental in our mental development”

IDIBELL is among the 120 top research centers in the world

The Scimago international ranking of Research Institutions places IDIBELL on 115th position among the 500 most highly-rated institutions in the world in all disciplines by its index and normalized impact with an excellence rate of 27.3. The report analyzes the scientific articles published by more than three thousand institutions in 104 different countries between 2005 […]

Leer más about IDIBELL is among the 120 top research centers in the world

Ferran Azorín: “Knowledge of basic mechanisms of epigenetics will allow us to develop new therapeutic strategies”

The laboratory of the Molecular Biology Institute of the CSIC in Barcelona led by Ferran Azorin, focuses its research on trying to understand the basic mechanisms that regulate genome function through epigenetics. The researcher has explained its latest advances in this field in the IDIBELL seminar series on November 25. One of the epigenetic factors […]

Leer más about Ferran Azorín: “Knowledge of basic mechanisms of epigenetics will allow us to develop new therapeutic strategies”

Jean-Ehrland Ricci: ”We investigate how targeting glycolysis may influence immune response anti-cancer”

The researcher at INSERM (French Institute for Health and Medical Research) Jean-Ehrland Ricci examines the correlation between glycolysis, cell death and immune response in tumor cells. He explained his latest developments in his research on IDIBELL seminar series November 18. Most cancer cells exhibit increased glycolysis for the generation of their energy supply (named the […]

Leer más about Jean-Ehrland Ricci: ”We investigate how targeting glycolysis may influence immune response anti-cancer”

DNA in my pocket

Some forty secondary and high school students of L’Hospitalet have had the opportunity to discover the research of IDIBELL during activities that the center has prepared to celebrate the Week of Science. As if they were real scientists, students carried out an experiment that they can easily repeat at home. They extracted their DNA, their […]

Leer más about DNA in my pocket

Described a new molecular mechanism altered in breast cancer development

About 10% of breast cancers are due to mutations in genes called BRCA1 and BRCA2. Still, it is not yet fully known the molecular mechanism that explains how the alteration of these genes greatly increases the risk of cancer. An international team led by the researcher of the IDIBELL and the Catalan Institute of Oncology […]

Leer más about Described a new molecular mechanism altered in breast cancer development

Louis Bouscail: “Our research in gene therapy must advance step by step. Our next challenge is to reach phase II of our clinical trial”

The gastroenterologist of the University Hospital of Rangueil, Touluse, and researcher at INSERM, Louis Buscail explained his latest advances in gene therapy for advanced pancreatic cancer in IDIBELL seminar series on 11 November. Currently, the only effective treatment for pancreatic cancer is surgery. The chemotherapeutic agent gemcitabine improves the survival of the patient but survival […]

Leer más about Louis Bouscail: “Our research in gene therapy must advance step by step. Our next challenge is to reach phase II of our clinical trial”
Scroll to Top